FibroBiologics Inc., a clinical-stage biotechnology company, has announced the successful completion of its third $5 million tranche as part of a $25 million Standby Equity Purchase Agreement with Yorkville Advisors Global, LP. This agreement allows the company to sell up to $25 million of its common stock over two years. The funds will be used for general corporate purposes, including advancing research and development programs and supporting a Phase 1/2 clinical trial for diabetic foot ulcers set to commence in late 2025. With over 275 patents, FibroBiologics focuses on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials. The recent funding marks a significant step in the company's expansion efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.